Performance vs S&P 500

03
Tracked Q1 2025–Q2 2026 +148.3%
S&P 500 total return (same window) +37.0%
Excess return +111.3%

Annualized: +107.1% · S&P 500: +28.7%

Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.

Priceable coverage: 99.6% · Options excluded: 0.0%

Sector breakdown

04
Healthcare 66.3%
Other/Unmapped 33.7%

Full portfolio 21 positions

05
Type Streak 8Q trend
Unknown issuer (CUSIP: 482931102) $497,509,394 29.58% 22,583,268 Up ×1
HTFL Heartflow, Inc. - Common Stock $247,868,956 14.74% 8,448,158 $-6,334,728 Down ×2
NAMS NewAmsterdam Pharma Company N.V. - Ordinary Shares $129,004,522 7.67% 3,806,566 $-104,878,656 Down ×1
SVRA Savara, Inc. - Common Stock $108,419,826 6.45% 17,600,621 $12,320,435
ALKS Alkermes plc - Ordinary Shares $101,538,262 6.04% 1,937,938 $79,968,662 Up ×1
SLDB Solid Biosciences Inc. - Common Stock $97,990,102 5.83% 9,808,819 $27,366,605
PHVS Pharvaris N.V. - Ordinary Shares $92,519,101 5.50% 2,675,509 $16,935,972
OLMA Olema Pharmaceuticals, Inc. - Common Stock $88,636,465 5.27% 7,085,249 $-22,789,514 Down ×2
Unknown issuer (CUSIP: 423494103) $60,604,500 3.60% 1,650,000 Up ×1
CABA Cabaletta Bio, Inc. - Common Stock $53,620,894 3.19% 17,241,445 $27,589,428 Up ×1
XFOR X4 Pharmaceuticals, Inc. - Common Stock $37,208,011 2.21% 7,967,454 $4,302,426
DNTH Dianthus Therapeutics, Inc. - Common Stock $35,333,576 2.10% 362,470 $4,915,094
CCCC C4 Therapeutics, Inc. - Common Stock $33,492,820 1.99% 7,171,910 $14,630,697
KYTX Kyverna Therapeutics, Inc. - Common Stock $25,705,350 1.53% 2,885,000 $-1,133,950 Down ×1
ANNX Annexon, Inc. - common stock $25,339,444 1.51% 4,437,731 $-3,538,770 Down ×2
RPID Rapid Micro Biosystems, Inc. - Class A Common Stock $14,591,789 0.87% 8,434,560 $-4,554,662
IRON Disc Medicine, Inc. - Common Stock $10,329,855 0.61% 141,234 $1,299,353
AVIR Atea Pharmaceuticals, Inc. - common stock $9,651,721 0.57% 2,075,639 $-3,048,511 Down ×2
Unknown issuer (CUSIP: 98422T209) $6,361,322 0.38% 664,021 $776,905
UPB Upstream Bio, Inc. - Common Stock $4,158,567 0.25% 600,949 $-3,646,332 Down ×3
NAMSW NewAmsterdam Pharma Company N.V. - Warrant $2,136,979 0.13% 99,999 $132,999

Biggest new bets

09

New positions opened this quarter, largest first.

SecurityValueShares% of portfolio
Unknown issuer (CUSIP: 482931102) $497,509,394 22,583,268 29.58%
Unknown issuer (CUSIP: 423494103) $60,604,500 1,650,000 3.60%

Top movers (QoQ)

10
SecurityActionShares ΔValue Δ
NAMS Trimmed -3.5M -$104.9M
ALKS Bought more +1.3M +$80.0M
CABA Bought more +7.6M +$27.6M
SLDB Price move only +0 +$27.4M
OLMA Trimmed -388K -$22.8M
PHVS Price move only +0 +$16.9M
CCCC Price move only +0 +$14.6M
SVRA Price move only +0 +$12.3M
HTFL Trimmed -2.0M -$6.3M
DNTH Price move only +0 +$4.9M

Exited positions

11

Includes corporate events (mergers, delistings) — not all exits are sells

Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.

SecurityQuarterShares beforeValue beforePrice since exit
CDTX Dec. 31, 2025 3,020,990 $289,290,002 No longer tracked
NUVL Sept. 30, 2025 1,447,267 $110,426,472 No longer tracked
IRON Sept. 30, 2025 583,500 $30,902,160 25.9%
CNTA June 30, 2026 635,000 $25,222,200 No longer tracked
MRSN March 31, 2026 346,545 $10,025,547 No longer tracked
TNGX March 31, 2026 653,493 $5,789,948 6.3%
XLO March 31, 2026 7,372,686 $4,719,994 -4.8%
XFOR (filed as XFORXXXX) June 30, 2025 16,915,784 $3,998,891 76.3%
IPSC Dec. 31, 2025 3,538,609 $1,762,227 50.8%
IVVD Sept. 30, 2025 1,799,595 $1,286,710 -43.9%
NAUT June 30, 2025 1,072,421 $923,354 342.8%